CX157

CX157
Systematic (IUPAC) name
3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiine 10,10-dioxide
Clinical data
Legal status
  • Uncontrolled
Routes of
administration
Oral
Identifiers
ATC code None
PubChem CID 18687754
ChemSpider 13701383 YesY
Chemical data
Formula C14H8F4O4S
Molar mass 348.27 g/mol
  (verify)

CX157 (proposed trade name TriRima, formerly Tyrima) is a selective and reversible inhibitor of MAO-A (RIMA).[1] As of 2007 it was in phase II clinical trials for the treatment of depression.[2] In 2013, it was discontinued for both depression and anxiety.

References

  1. Fielding R, Mielach F, Free J, Pande A (2007). Pharmacokinetics and oral bioavailability of CX157, a reversible selective MAO-A inhibitor, in primates (PDF). 2007 AAPS Annual Meeting & Exposition. Retrieved 2009-06-14.
  2. Clinical trial number NCT00739908 at ClinicalTrials.gov



This article is issued from Wikipedia - version of the Wednesday, January 13, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.